ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2022 and some content may be unavailable. To unlock all content for 2022, please visit the archives.

Abstract: SA-PO695

Successful Treatment With Eculizumab in Patients With Severe ANCA Vasculitis

Session Information

Category: Glomerular Diseases

  • 1303 Glomerular Diseases: Clinical‚ Outcomes‚ and Trials


  • Uriol Rivera, Miguel, Hospital Universitari Son Espases, Palma de Mallorca, Illes Balears, Spain
  • Arrufat Goterris, Gemma, Hospital Universitari Son Espases, Palma de Mallorca, Illes Balears, Spain
  • Obrador, Aina, Hospital Universitari Son Espases, Palma de Mallorca, Illes Balears, Spain
  • Garcia-Alvarez, Angel, Hospital Comarcal d'Inca, Inca, Illes Balears, Spain
  • Jimenez, Sonia, Hospital Universitari Son Espases, Palma de Mallorca, Illes Balears, Spain

Severe presentation of ANCA vasculitis is a life-threatening disease despite aggressive immunodepression therapy. Complement hyperactivation is involved in pathogenesis; thus, the effect of the C5 inhibitor (eculizumab) used in severe forms of ANCA vasculitis may be a treatment option.


This is a retrospective study. Nine patients were included. Period of study: from May 2017 to May 2022. All patients received at least 3 drugs (steroids, rituximab and mycophenolate or cyclophosphamide) before eculizumab. Eculizumab was indicated as an off-label indication due to lack of improvement or clinical worsening.


Mean (SD) age: 62 (15) years. Female: 4. Three patients showed serum anti-proteinase 3 antineutrophil cytoplasmic antibody (PR3-ANCA) and 5 (myeloperoxidase: MPO-ANCA) and one was ANCA-negative. Six patients had an estimated glomerular filtration rate (eGFR) < 10 ml/min/1.73 m2 at presentation. Five patients had pulmonary involvement. The mean (min-max) time of follow-up after the onset of eculizumab was 27 (1-60) months. One patient ANCA-negative microscopic polyangiitis with diffuse alveolar hemorrhage needed orotracheal intubation and had a satisfactory evolution after eculizumab; however, 20 days after, the patient developed a COVID-19 infection and died. One patient who needed urgent dialysis at presentation did not recover renal function and showed a complement factor H mutation. The evolution of the other 7 patients was as follows: the median (p25-p75) eGFR increased from baseline to the end of the follow-up: 9.1(4.8-21.7)ml/min/1.73m2 to 31(13–45)ml/min/1.73m2, respectively (P=0.018) and the mild proteinuria disappeared in all patients. Alveolar hemorrhage improved in all patients within seven days after the first eculizumab administration. The median (p25-p75) doses of eculizumab administered were 1800(1800-3600) mg. One patient required eculizumab for two different periods.


One patient died due to a COVID-19 infection, and one remained in chronic renal replacement therapy.
Alveolar hemorrhage was well controlled in all patients.
The eGFR increased significantly in 7/9 patients, and in 4/6 patients, dialysis could be withdrawn.
In severe ANCA vasculitis, eculizumab should be considered for improving outcomes.


  • Other NIH Support